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Background: Similar to lipid emulsion propofol, microemulsion propofol also causes a high incidence of pain 
during intravenous injection. Various methods have been used to minimize the incidence and severity of pain on 
injection of lipid emulsion propofol. In this study, we investigated the effect of a lidocaine mixture on pain induced 
by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain 
on injecting a propofol-lidocaine mixture.
Methods: One hundred sixty (n = 160) patients of American Society of Anesthesiologists physical status class I or 
II were randomly allocated to four groups: Group A, control; Group B, 20 mg lidocaine; Group C, 30 mg lidocaine; 
Group D, 40 mg lidocaine. In each patient, pain on microemulsion propofol solution injection was graded as none, 
mild, moderate, or severe.
Results: The incidence of pain in groups A, B, C, and D was 97.5%, 80%, 65%, and 50%, respectively. Increasing the 
lidocaine dose significantly reduced pain (P < 0.05). One patient in Group D (2.5%) had moderate to severe pain, 
which was significantly lower than groups B (42.5%) and C (32.5%) (P < 0.05). 
Conclusions: The lidocaine and propofol mixture is effective in alleviating pain associated with microemulsion 
propofol injection. Within this dose range and in this patients population, increasing lidocaine dosage significantly 
reduced pain during injection of microemulsion propofol. (Korean J Anesthesiol 2010; 59: 310-313)
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Introduction
    Lipid emulsion propofol (2,6-diisopropylphenol), an intra-
venous (IV) anesthetic, is commonly used for general anesthesia 
because of its rapid onset, short duration, and the excellent 
quality of recovery it provides. Nevertheless, lipid emulsion 
propofol has been associated with several drawbacks [1-3], and 
the incidence of pain secondary to lipid emulsion propofol 
injection varies from 59.1% to 100%, when injection is made 
into a vein on the dorsum of the hand [4,5].
    Lipid-free microemulsion propofol (Aquafol
TM, Daewon 
Pharmaceutical Co., Ltd., Seoul, Korea) was newly developed to 
reduce the risk of lipid solvent-related adverse drug reactions. 
However, pain on the injection of microemulsion propofol is 
still an unresolved problem [6], which not only causes distresses 
in patients, but also present challenges to the anesthesiologists.
    The mechanism of pain on propofol injection remains unclear 
and requires further investigations. Although various methods 
have been attempted to attenuate this injection pain [4,7-17], 
adding lidocaine to propofol is the most popular method. 
    In the present study, we sought to evaluate the efficacy of 
lidocaine in minimizing microemulsion propofol injection pain, 
and to determine the optimal dose of lidocaine to be added to 
microemulsion propofol. 
Materials and Methods
    The Institutional Review Board of our institution approved 
the study protocol, and written consent was obtained from 
all patients prior to study enrollment. One hundred sixty (n = 
160) American Society of Anesthesiologists physical status I 
and II patients, aged 16-65 years, and scheduled for elective 
surgery, were selected. Patients with allergies to any drugs 
or renal, hepatic, or cardiac problems, neurologic deficits or 
psychiatric disorders were excluded. None of the patients 
was premedicated before entering the operation room, and 
all had a 20-gauge cannula placed into a vein on the dorsum 
of the nondominant hand. Standard monitoring, including 
electrocardiography, noninvasive arterial pressure, pulse 
oximetry, capnography, and body temperature, was performed 
throughout the procedure.
    Patients were randomly allocated into one of four groups. 
Patients in Group A were injected intravenously with 12 ml of 
microemulsion propofol plus 3 ml of saline. Patients in Group 
B were injected intravenously with 12 ml of microemulsion 
propofol, 2 ml of saline, and 1 ml of 2% lidocaine (20 mg). 
Patients in Group C were injected intravenously with 12 ml 
of microemulsion propofol, 1.5 ml of saline, and 1.5 ml of 
2% lidocaine (30 mg). Patients in Group D were injected 
intravenously with 12 ml of microemulsion propofol, 1 ml 
of saline, and 2 ml of 2% lidocaine (40 mg). No significant 
difference was observed in patient characteristics (Table 1).
    Propofol was drawn up into a polyethylene syringe by an 
assistant and made up to a total volume of 15 ml using saline, 
as necessary. All drugs were kept at room temperature and 
administered within 20 minutes of preparation. In a double-
blind manner, propofol solution was manually injected by 
an anesthesiologist at a rate of 3 ml every 5 seconds until the 
patient lost consciousness. All patients were questioned every 
5 seconds during the injection regarding pain or discomfort in 
the arm. The scale of pain was then recorded. The pain scale 
was defined as follows: no pain; mild pain (tolerable soreness or 
slight pain); moderate pain (subjective complaint between mild 
and severe pain); severe pain (pain causing the patient to flex 
his/her arm to deny injection). If the patient lost consciousness 
before injecting 15 ml of the solution, the remaining portion 
would not be administered. We also recorded the time losing 
consciousness. After recovering from anesthesia, patients were 
asked if they had any recollection of discomfort or pain during 
the induction period. 
    Statistical analyses were performed using SPSS (version 17.0, 
SPSS Inc., Chicago, IL, USA). The differences in mean pain-
intensity scores among the groups were analyzed with the chi-
square test for trends. The time of unconsciousness among the 
groups did not follow a normal distribution, and were analyzed 
with one-way ANOVA using log-transformed data, followed by 
Scheffe post hoc test. P value < 0.05 was considered statistically 
significant.
Table 1. Demographic Data
A (n = 40) B (n = 40) C (n = 40) D (n = 40)
Age (yr)
Weight (kg)
Height (cm)
Gender (M/F)
ASA (I/II)
40.9 ± 13.0
65.6 ± 12.0
168.9 ± 9.3
25/15
33/7
37.9 ± 14.7
63.5 ± 8.2
166.4 ± 7.6
23/17
34/6
42.2 ± 13.4
63.2 ± 11.3
165.5 ± 8.7
20/20
28/12
40.45 ± 14.7
64.5 ± 11.5
165.2 ± 7.4
25/15
32/8
Values are presented as means ± SD. Group A receive 12 ml of microemulsion propofol plus 3 ml of saline, Group B receive 12 ml of 
microemulsion propofol, 2 ml of saline, and 1 ml of 2% lidocaine (20 mg), Group C receive 12 ml of microemulsion propofol, and 1.5 ml of 
saline, and 1.5 ml of 2% lidocaine (30 mg), Group D receive 12 ml of microemulsion propofol, 1 ml of saline, and 2 ml of 2% lidocaine (40 mg). 
There is no significant difference between the groups. ASA: American Society of Anesthesiologists Physical Status.312 www.ekja.org
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Results
    The number of patients in each group who experienced 
pain or discomfort is shown in Table 2. The incidence of pain 
in groups A (control), B, C, and D was 97.5%, 80%, 65%, and 
50%, respectively. Increasing the lidocaine dosage significantly 
reduced pain (P < 0.05). The incidence of moderate to severe 
pain was 85% in the control group and that in the other groups 
was 42.5% (Group B), 32.5% (Group C), and 2.5% (Group D) (P 
< 0.05). 
    Loss of consciousness was more rapid in Group A than in all 
other groups (P < 0.05, Table 3). In the recovery room, only one 
patient who reported pain was unable to recall pain scale and, 
all patients except one reported the same pain scale at the time 
of anesthesia induction.
Discussion
    Microemulsion propofol, consists of 1% propofol, 8% poly-
ethylene glycol 660 hydroxystearate (Solutol HS 15, BASF 
Co., Ltd., Seoul, Korea), and 5% tetrahydrofurfuryl alcohol 
polyethylene glycol ether (Glycofurol, Roche, Basle, Switzer-
land), is thermodynamically stable, because it does not contain 
a long chain triglyceride emulsion, unlike the original lipid 
emulsion propofol. This formulation avoids the risk of lipid 
solvent-related adverse drug reactions, such as fat embolism, 
postoperative infection, hypertriglyceridemia and pancreatitis 
[1-3]. However, similar to other existing propofol formulations, 
newly developed microemulsion propofol still causes pain on 
injection. In addition, microemulsion propofol produces more 
frequent (69.7-89%) and severe pain (51%) upon injection than 
long-chain triglyceride propofol [6,18]. In our study the overall 
incidence of pain was 97.5%, and 55% of patient experienced 
severe pain.
    The concentration of free propofol in the aqueous phase and 
activation of the enzymatic cascade of the plasma kallikrein-
kinin system are associated with the intensity of pain upon 
injection [19,20]. Higher aqueous free propofol concentrations 
of microemulsion propofol produce more frequent and severe 
pain [6]. However, the mechanism of pain upon injection of 
propofol is still unclear and requires further investigation. 
Various methods have been attempted to attenuate this 
injection pain. They include prior administration of opioid [7], 
lidocaine [7], prilocaine [8], thiopental [9], metocloproamide 
[10], ondansetron [11], ephedrine [12], the addition of 10-40 
mg lidocaine to the propofol emulsion [4,13,14], cooling the 
propofol to 4
oC before injection [15], and making use of the 
antecubital fossa vein for injection [16]. These methods do not 
eradicate pain completely, but do decrease the incidence or 
severity of injection pain. To date, adding lidocaine to propofol 
is the most popular method to reduce injection pain of lipid 
emulsion propofol. Indeed, 30 mg of lidocaine is the optimal 
dose typically used to reduce pain on injection [17]. Lidocaine 
mixed with lipid emulsion propofol reduces its pH, lowers 
propofol concentration in the aqueous phase, and results in 
reduced pain [21]. Lidocaine mixed with propofol is more 
effective than pretreatment with lidocaine for decreasing 
propofol injection pain [16]. The pH of microemulsion propofol 
(7.51 ± 0.01) is similar to that of the lipid emulsion, and aqueous 
free propofol concentration is seven times higher than that of 
lipid emulsion [6]. 
    It is well accepted that injecting through a large vein, such 
as the antecubital fossa vein, is an effective way to reduce 
pain on propofol injection. This is presumably because the 
drug contacts the mid-stream in the venous lumen and due 
to reduced contact with the sensitive vein wall. The drug may 
also be buffered effectively by the blood, with which it can 
mix freely [16]. Nonetheless, a cannula is usually placed into 
a vein on the dorsum of the nondominant hand, because 
many anesthesiologists prefer ease of access, ease of detecting 
extravasation, and there is a low incidence of neural or arterial 
damage. Premedications, such as benzodiazepine, analgesic 
Table 2. Incidence of Pain Reported at the Time of Anesthesia 
Induction
Group
No pain
n (%)
Mild
n (%)
Moderate
n (%)
Severe
n (%)
A
B
C
D
1 (2.5)
8 (20.0)
14 (35.0)
20 (50.0)
5 (12.5)
15 (37.5)
13 (32.5)
19 (47.5)
12 (30.0)
12 (30.0)
10 (25.0)
0 (0.0)
22 (55.0)
5 (12.5)
3 (7.5)
1 (2.5)
Group Areceive 12 ml of microemulsion propofol plus 3 ml of saline, 
Group B receive 12 ml of microemulsion propofol, 2 ml of saline, and 
1 ml of 2% lidocaine (20 mg), Group C receive 12ml of microemulsion 
propofol, and 1.5 ml of saline, and 1.5 ml of 2% lidocaine (30 mg), 
Group D receive 12 ml of microemulsion propofol, 1 ml of saline, and 
2 ml of 2% lidocaine (40 mg).
Table 3. The Time of Unconsciousness
Group Time of unconsciousness (sec)
A
B
C
D
40.2 ± 16.0
46.0 ± 10.1*
52.6 ± 12.7*
48.3 ± 9.0*
Values are presented as mean ± SD. Group Areceive 12 ml of 
microemulsion propofol plus 3 ml of saline, Group B receive 12 ml of 
microemulsion propofol, 2 ml of saline, and 1 ml of 2% lidocaine (20 
mg), Group C receive 12 ml of microemulsion propofol, and 1.5 ml of 
saline, and 1.5 ml of 2% lidocaine (30 mg), Group D receive 12 ml of 
microemulsion propofol, 1 ml of saline, and 2 ml of 2% lidocaine (40 
mg). *P < 0.05 compared with Group A.313 www.ekja.org
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opioid, and anticholinergics appears to have little effect on the 
incidence of pain during propofol injection [22-24], but other 
premedications, such as hydroxyzine may reduce pain severity 
[25], so we did not premedicate. 
    Lidocaine may induce cardiovascular, neurotoxic and 
other complications. However, less than 1 mg/kg can be used 
safely [26]. Thus, our study applied 20-40 mg of lidocaine. 
The results of this study show the effect of adding lidocaine to 
microemulsion propofol in reducing pain during injection.
    More study is needed, as the loss of consciousness was 
more rapid in Group A than in all other groups. Similar to our 
findings, two other studies suggested decreased anesthetic 
potency of propofol when administered as lidocaine mixed with 
propofol in rats [27] and women [10]. In contrast to our finding, 
two studies showed clinically insignificant effects in the study 
ranged from 200 : 10 to 200 : 50 propofol/lidocaine mg ratio [28] 
and 10 : 1 propofol 1%/lodocaine1% volume ratio [29].
    In conclusion, a lidocaine and propofol mixture is effective 
in alleviating pain associated with microemulsion propofol 
injection. Within this dose range and in this patients population, 
increasing lidocaine dosage significantly reduced pain during 
injection of microemulsion propofol.
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